Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rx Drug Importation Enforcement Reverts To FDA After Customs Stops Interdictions

This article was originally published in The Pink Sheet Daily

Executive Summary

Move could enable patients to receive small amount of medicine, suggests Sen. Bill Nelson (D-Fla.).

You may also be interested in...



Drug Importation Provision Included In Homeland Security Conference Report

Conferees on the Appropriations bill agreed to a limited form of personal importation from Canada.

GAO Recommends Strategic Framework To Limit Prohibited Drug Importation

Study, commissioned by Senate Permanent Subcommittee on Investigations, highlights the need to accurately define the scope of prohibited drug importation.

Novartis Institute For Tropical Diseases Could Have TB Drug In Clinic By Late 2007

Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS063312

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel